RELAFEN Drug Patent Profile
✉ Email this page to a colleague
When do Relafen patents expire, and when can generic versions of Relafen launch?
Relafen is a drug marketed by Smithkline Beecham and is included in one NDA.
The generic ingredient in RELAFEN is nabumetone. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the nabumetone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Relafen
A generic version of RELAFEN was approved as nabumetone by CHARTWELL RX on February 25th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RELAFEN?
- What are the global sales for RELAFEN?
- What is Average Wholesale Price for RELAFEN?
Summary for RELAFEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 109 |
Clinical Trials: | 3 |
Patent Applications: | 4,596 |
DailyMed Link: | RELAFEN at DailyMed |
Recent Clinical Trials for RELAFEN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sanford Research | Early Phase 1 |
Dr. Reddy's Laboratories Limited | Phase 1 |
US Patents and Regulatory Information for RELAFEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-001 | Dec 24, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-002 | Dec 24, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RELAFEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-001 | Dec 24, 1991 | ⤷ Sign Up | ⤷ Sign Up |
Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-002 | Dec 24, 1991 | ⤷ Sign Up | ⤷ Sign Up |
Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-002 | Dec 24, 1991 | ⤷ Sign Up | ⤷ Sign Up |
Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-001 | Dec 24, 1991 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RELAFEN
See the table below for patents covering RELAFEN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Switzerland | 603525 | ⤷ Sign Up | |
United Kingdom | 1474377 | ⤷ Sign Up | |
Belgium | 819794 | ⤷ Sign Up | |
France | 2242972 | ⤷ Sign Up | |
Denmark | 119384 | ⤷ Sign Up | |
Switzerland | 599090 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |